700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Short Communication Open Access
A new study investigates about the activity of a new SFK inhibitor in RMS. SI221 is a pyrazolo [3,4-d] pyrimidine derivative able to reduce both apoptosis and differentiation in eRMS and aRMS. SFKs are frequently overexpressed in RMS and their inhibition can be a good strategy for RMS treatment. Rhabdomyosarcoma (RMS) represents approximately half of the total pediatric soft tissue sarcoma (STS), slightly more frequent in males but equally distributed across racial groups . RMS is characterized by the expression of genes involved in the early myogenesis which fail to complete differentiation and cell cycle arrest . It can be divided into 2 major histological subtypes: embryonal (eRMS), mostly found in childhood, and alveolar (aRMS) common in both children and adults .
Pediatric, Soft, Tissue, Sarcoma, Pediatric, Soft, Tissue, Sarcoma